APMA has the resources you need to help you through every step of your career. With detailed information about MIPS and recent coding trends along with compliance guidelines and practice marketing materials, APMA has you covered whether you are just getting started in practice, preparing for retirement, or anywhere in between.
Today's podiatrist has the necessary education and training to treat all conditions of the foot and ankle and plays a key role in keeping America healthy and mobile while helping combat diabetes and other chronic diseases.
Your feet are excellent barometers for your overall health. Healthy feet keep you moving and active. They are quite literally your foundation. In this section, learn more about APMA Seal-approved and accepted products, proper foot care, common foot and ankle conditions, and how your podiatrist can help keep you and your feet healthy.
APMA is the only organization lobbying for podiatrists and their patients on Capitol Hill. As the voice of podiatric medicine to your legislators and regulators, APMA is active on a variety of critical issues affecting podiatry and the entire health-care system.
At the end of last week, APMA submitted comments to all seven Part B Medicare Administrative Contractors in conjunction with APMA’s Contractor Advisory Committee (CAC) representatives to address concerns with draft Local Coverage Determinations (LCDs) and Local Coverage Articles (LCA) related to use of skin substitute products (also referred to as Cellular and/or Tissue Based Products, or CTPs) used for the treatment of diabetic foot ulcers (DFU) and Venous Leg Ulcers (VLU).
As indicated in a previous Weekly Focus, on April 25, all 7 Part B MACs in the country released identical Proposed LCDs and accompanying Proposed LCAs for the use of skin substitutes/CTPs for treating DFUs and VLUs. One of the proposals provided that coverage only be allowed for skin substitute grafts/CTPs that have peer-reviewed, published evidence supporting their use. Another proposal limited the number of applications to no greater than four within the episode of skin replacement therapy other than “in exceptional cases in which four applications is not sufficient for adequate wound healing.” These proposals were subject to comment. APMA and its appropriate committees, in conjunction with APMA’s national network of CAC representatives, reviewed these proposals and contributed to the preparation of APMA’s comments. APMA supported the CAC representatives in their efforts by coordinating attendance at CAC meetings, sharing bullet points for discussion, and sharing draft letters for submission by APMA in conjunction with the CAC representatives.
APMA provided comments on the following items, among others:
Members can read these letters, as well as all other past comment letters, at www.apma.org/CommentLetters. If you have questions or concerns, contact the APMA Health Policy and Practice department at healthpolicy.hpp@apma.org.
—
Learn MoreSignificant Changes to Steroid HCPCS Coding
—
Learn More11400 Rockville Pike, Suite 220
Rockville, MD 20852
301-581-9200
Contact Us
Copyright © 2024 American Podiatric Medical Association